The Marfella et al. (2024) study in the NEJM is the most significant clinical evidence to date linking microplastics to hard cardiovascular outcomes in humans. This was a prospective observational study of 304 patients undergoing carotid endarterectomy. Excised atheromatous plaques were analyzed using pyrolysis-gas chromatography/mass spectrometry, electron microscopy, and immunohistochemistry. Polyethylene was the most common polymer detected (mean 21.7 +/- 24.5 micrograms per mg of plaque in positive samples). Plaques containing microplastics showed higher levels of inflammatory markers (CD68+ macrophages, IL-18, IL-1beta) and greater evidence of oxidative damage. The adjusted hazard ratio for MACE (major adverse cardiovascular events) in the microplastic-positive group was 4.53 (95% CI 2.00-10.27; p<0.001). While this is an observational study and cannot prove causation, the dose-response relationship between microplastic concentration and inflammatory markers strengthens the case for a causal link [1].
The chemical additive pathway is well-established in toxicology. Hahladakis et al. reviewed the migration of chemical additives from plastics and documented that phthalates (DEHP, DBP), bisphenols (BPA, BPS, BPF), brominated flame retardants (PBDEs), and organotin stabilizers all leach from common food-contact plastics under normal use conditions. Migration rates increase substantially with temperature, contact time, and fat content of food. Many of these chemicals have established toxicological profiles as endocrine disruptors at environmentally relevant concentrations [2].
Regarding endocrine disruption specifically, the evidence links plastic-associated chemicals to multiple systems. Phthalates are anti-androgenic and have been associated with reduced sperm quality, altered male reproductive development (hypospadias, cryptorchidism), and preterm birth. BPA is estrogenic and has been linked to polycystic ovary syndrome, obesity, type 2 diabetes, and cardiovascular disease in epidemiological studies. The concern with microplastics as a delivery mechanism is that they may bypass normal exposure routes (e.g., gastrointestinal first-pass metabolism) and deliver additives directly to tissues where they accumulate [3].
Prata et al. reviewed the toxicological evidence from animal models and found consistent effects across species: gut microbiome disruption, intestinal barrier dysfunction, hepatic lipid accumulation, neurotoxicity (behavioral changes and neuroinflammation), and reproductive toxicity (reduced fertility, altered gonadal development). They noted that nanoplastics, due to their ability to cross cell membranes and the blood-brain barrier, may pose greater risks than larger microplastics, but are also harder to detect and study [4].
Rahman et al. synthesized the evidence on microplastic accumulation in human organs. Post-mortem and surgical studies have now detected microplastics in human lung tissue, liver, spleen, kidney, placenta, and brain tissue in addition to blood. The long-term consequences of this tissue accumulation remain unknown, but the parallel to other particulate exposures (asbestos, PM2.5) -- where chronic low-grade inflammation drives fibrosis and carcinogenesis over decades -- is a serious concern raised by multiple research groups [5].
The Lancet Planetary Health Commission (2023) concluded that the health effects of the global plastics crisis are "poorly quantified but potentially large," and called for urgent epidemiological research, regulatory action on the most hazardous plastic additives, and application of the precautionary principle given the ubiquity of exposure and the plausibility of harm [6].